Diamine platinum(IV) complexes having mixed carboxylate ligands as antitumor agents
AssigneeBoard of Regents, The University of Texas System
InventorsAbdul R. Khokhar, Zahid H. Siddik, Salaam Al-Baker
Life of this patent
Estimating the term…
Abstract
Platinum(IV) complexes with mixed carboxylato ligands having the formula: ##STR1## where X.sup.1 and X.sup.2 are carboxylato, or are jointly dicarboxylato, where .sup.1 Y and Y.sup.2 are carboxylato, and where Z is either diaminocyclohexane or ethylenediamine, have been found to have desirable antitumor activity, as well as relatively low levels of toxicity.
Claims12
A platinum(IV) complex having the formula ##STR5## or a stereoisomer thereof, where X.sup.1 and X.sup.2 are carboxylato or are jointly dicarboxylato, where Y.sup.1 and Y.sup.2 are carboxylato, and where Z is a bidentate ligand selected from the group consisting of diaminocyclohexane and ethylenediamine.
An antitumor composition which includes (a) an amount effective to inhibit neoplastic cell growth of a platinum(IV) complex having the formula ##STR6## or a stereoisomer thereof where X.sup.1 and X.sup.2 carboxylato or are jointly dicarboxylato, where Y.sup.1 and Y.sup.2 are carboxylato, and where Z is a bidentate ligand selected from the group consisting of diaminocyclohexane and ethylenediamine, and (b) a pharmaceutically acceptable carrier.
A method of inhibiting neoplastic cell growth, including the step of administering to a mammal an amount effective to inhibit neoplastic cell growth of a platinum(IV) complex having the formula ##STR7## or a stereoisomer thereof, where X.sup.1 and X.sup.2 are carboxylato or are jointly dicarboxylato, where Y.sup.1 and Y.sup.2 are carboxylato, and where Z is a bidentate ligand selected from the group consisting of diaminocyclohexane and ethylenediamine.
Dependencies are inferred from the claim text.